Xavier Luria is the new partner and strategy advisor of FreeOx Biotech, in a bid to accelerate development and the regulatory process for its main drug candidate, Ox-01, to treat stroke.
Luria, linked to CataloniaBio & HealthTech, is a world-renowned expert in clinical and regulatory drug development. Since 2012, he has been an independent senior consultant in Drug Development and Regulation (DDR) with offices in Barcelona and London. He was head of Safety and Efficacy of Medicines at the European Medicines Agency (EMA) from 2005 to 2012.
Xavier Luria highlights: “Given its advanced stage of development, Ox-01 could become a real therapeutic option to treat stroke within a few years.” The main researcher on the studies is Dr Angel Chamorro, head of the of the Functional Unit of Cerebral Vascular Pathology at Hospital Clinic Barcelona.
Photo: Carlos Lurigados, CEO of FreeOx Biotech, with Xavier Luria. ©FreeOx Biotech.
Comments